News

TECregen Wins Superpass Award at Bayer Co.Lab Connect Basel 2026

Recognition highlights TECregen's innovative approach to thymus regeneration and immune restoration

Basel, Switzerland, October 08, 2026 – TECregen is pleased to announce that it has received the Superpass Award at Bayer Co.Lab Connect Basel 2026, the event's main prize.

Selected among four Swiss biotech finalists, TECregen was recognized for its innovative platform developing next-generation, tissue-targeted and functionally selective thymopoietic therapies designed to regenerate the thymus and restore immune function.

The award followed a presentation by Dr. Ignacio Moraga, Chief Scientific Officer of TECregen, showcasing the company's approach to developing regenerative biologics aimed at improving immune competence and resilience.

The Superpass Award includes CHF 50,000 in support through Superlab Suisse and provides opportunities to connect with Bayer's global network of scientific experts, investors and industry partners.

This recognition marks another important milestone for TECregen as the company continues to advance its thymus regeneration platform towards clinical development.

TECregen extends its sincere thanks to Bayer Co.Lab and its partners for this recognition and for supporting innovation within Switzerland's life sciences ecosystem.

Read Bayer's official announcement:
https://www.linkedin.com/posts/startups-ugcPost-7514026145843945472-lb8P/